Clinical trials
Autoimmune clinical trials
Below are recruiting autoimmune clinical trials, each written for real people, not researchers. We’re tracking 339 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07536529Recruiting
Oxidative Stress in Autoimmune Joint Diseases
This study looks at a type of cellular damage called oxidative stress in people with autoimmune joint diseases like rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Researchers want to understand how this damage relates to your disease and may help develop better treatments.
Larissa, ThessalyAges 18 years+ - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07516964Recruiting
Studying autoimmune kidney disease in children and adults
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
Rochester, MinnesotaAges birth–99 years - NCT07513181RecruitingPhase 2
Testing ATH-063 for Hard-to-Treat Ulcerative Colitis
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
Miami, FloridaAges 18–75 - NCT07515638Recruiting
Immune System Study for Autoimmune Diseases
This research study collects samples and information from people with rheumatoid arthritis, lupus, or scleroderma, plus healthy volunteers, to better understand how the immune system works in these conditions. By comparing these groups, researchers hope to find new ways to treat and manage autoimmune diseases.
MontpellierAges 18 years+ - NCT05697159Recruiting
7-tesla brain MRI to study how filgotinib eases RA pain
This trial uses a very high-strength brain MRI to understand how the RA medicine filgotinib may reduce pain. If you have active rheumatoid arthritis and can safely complete the scan, the study may help researchers better target pain relief in RA.
GlasgowAges 18–74 - NCT07473154RecruitingPhase 1/Phase 2
Calming an overactive immune system with special cells
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
DüsseldorfAges 18 years+ - NCT06781437Recruiting
Lymphoma medical record review study
This study looks back at the medical records of people with lymphoma to learn more about the disease. It does not involve any new treatments or tests—just reviewing what happened in the past.
Bologna, BolognaAges 18 years+ - NCT07480720Recruiting
Thyroid autoimmunity and eye changes in Graves disease
This study looks at how inflammation and thyroid autoimmunity in Graves disease may cause changes in the retina at the back of the eye. It uses a special eye scan (OCT) to measure those changes and compares results between people with Graves disease and healthy volunteers.
Elâzığ, ElaziğAges 18 years+ - NCT06779799Recruiting
Study of vocal cord lesions in autoimmune disease patients
This study examines vocal cord lesions, like 'bamboo' nodes, that cause voice changes (dysphonia) in people with autoimmune diseases such as lupus or rheumatoid arthritis. It aims to better understand and characterize these lesions to improve diagnosis and treatment.
BrestAges 18 years+ - NCT06787989RecruitingPhase 1
BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Chengdu, SichuanAges 18–60 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT02103361Recruiting
Pregnancy registry for Stelara or Tremfya exposure
This study is a pregnancy exposure registry. It collects information to better understand pregnancy outcomes after exposure to Stelara or Tremfya (medicines used for autoimmune diseases).
La Jolla, CaliforniaAges Any age - NCT07456358Recruiting
Immune attack targets in brain disease
This study looks at the immune system's role in neurological problems caused by cancer immunotherapy or autoimmune diseases. Researchers will collect spinal fluid to find out which immune targets are involved, which may help improve diagnosis and treatment.
Le Kremlin-BicêtreAges 18 years+ - NCT07453368RecruitingPhase 2
Orelabrutinib for relapsed or hard-to-treat AIHA
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Beijing, Beijing MunicipalityAges 18–85 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07413874Recruiting
Music therapy over video for depression and hormone disorder
This trial tests if telehealth music therapy can help adults who have both an endocrine autoimmune disease and depression. You'll join sessions from home using Zoom.
Boone, North CarolinaAges 18–65 - NCT07400224RecruitingPhase 1/Phase 2
New PET imaging test for cancer, heart, or immune disease
This study tests a new type of PET scan using a special tracer called Al18F-NOTA-FAPI-04 to see if it can better detect cancer, heart disease, or immune system conditions. The goal is to find out how well this imaging method works for diagnosis or monitoring of these diseases.
BeijingAges 18–88 - NCT07388459Recruiting
Study of autoimmune atrophic gastritis over time
This study follows people with autoimmune atrophic gastritis to understand how the condition changes over time and what symptoms or complications may arise. It aims to collect information that could improve future care.
Pavia, PaviaAges 18 years+ - NCT07371468RecruitingPhase 1
Study of an experimental drug for lupus, rheumatoid arthritis, and related conditions
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Buenos AiresAges 18–70 - NCT07362654Recruiting
Gluten challenge study in kids with celiac disease
This study looks at how the immune system of children with celiac disease responds to a small amount of gluten. It may help researchers understand the disease better and find new ways to monitor it.
MálagaAges 8–14 - NCT07366866RecruitingPhase 1
Safety study of an experimental drug in healthy adults
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07348432Recruiting
Insulin delivery and eating behaviors in type 1 diabetes
This study looks at how different insulin delivery methods (like injections or pumps) affect eating behaviors in people with type 1 diabetes. By joining, you may help researchers learn how to improve care and quality of life.
Montreal, QuebecAges 12 years+
Hear when a new Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune?
- Yes. Clin2 currently lists 339 recruiting autoimmune studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.